Rademacher J, Pletz M W, Welte T
Abteilung Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, Hannover, Germany.
Internist (Berl). 2010 Dec;51(12):1510-5. doi: 10.1007/s00108-010-2716-0.
Bronchiectasis has become more rarely because of the development of antibiotic therapy and vaccination. At present the great majority of bronchiectasis is more likely caused by congenital disorders than by infective reasons. Therapeutic strategies based on the experiences from cystic fibrosis and chronic obstructive pulmonary disease are not always conferrable to patients suffering from bronchiectasis. There are not enough controlled studies to give evidence-based recommendations in the treatment of bronchiectasis, which are not associated with cystic fibrosis. Goals in the treatment are improvement of the mucociliar clearance, the therapy of infections and treatment of inflammation. Currently several agents are under examination. To improve the prognosis and therapy options it would be reasonable to build up a national register for patients with bronchiectasis.
由于抗生素治疗和疫苗接种的发展，支气管扩张症已变得较为罕见。目前，绝大多数支气管扩张症更可能是由先天性疾病而非感染原因引起的。基于囊性纤维化和慢性阻塞性肺疾病经验的治疗策略并不总是适用于支气管扩张症患者。目前尚无足够的对照研究为非囊性纤维化相关支气管扩张症的治疗提供循证推荐。治疗目标是改善黏液纤毛清除功能、治疗感染和炎症。目前有几种药物正在进行研究。为改善预后和治疗选择，建立一个全国性的支气管扩张症患者登记系统是合理的。
